Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond
{{output}}
Background: Metastatic renal cell carcinoma (mRCC) represents a significant challenge due to variable patient outcomes despite advancements in treatment. Nivolumab, a programmed death-1 (PD-1) inhibitor, has demonstrated efficacy... ...
